A first case report of diffuse acneiform eruption caused by capecitabine in a patient with small-cell neuroendocrine lung carcinoma. (October 2016)

• Record Type: Journal Article
• Authors: Kara, Asude; Alatas, EmineTugba; Dogan, Gursoy; Celik, Serkan Y; Tanriverdi, Ozgur
• Is Part Of: Journal of oncology pharmacy practice. Volume 22:Number 5(2016)
• Page Start: 717
• Page End: 719
• Publication Date: 2016-10
• Subjects: Capecitabine -- chemotherapeutic agent -- acneiform drug eruption; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155215587542
• Languages: English
• ISSNs: 1078-1552

Abstract

Capecitabine is a chemotherapeutic agent which is converted to fluorouracil by thymidine phosphorylase in human body. It is one of the commonly used agents in colorectal and metastatic breast cancers. Hand-foot syndrome is most commonly observed adverse effect of capecitabine; however, it has several adverse cutaneous and mucosal effects. To the best of our knowledge, no case with acneiform eruption has been reported so far. Here, we presented a 54-year-old man with development of capecitabine-related acneiform drug eruption.